Cedric Dos Santos
Global Product Leader AstraZeneca
Cedric is a highly motivated Ph.D. research scientist with 9+ years of pre-clinical and translational research in the field of Hematology/Oncology, especially Acute Myeloid Leukemia (AML).
He is an expert in normal/malignant stem cells, signal transduction, biomarkers, and drug discovery/drug development using small molecules or cancer immunotherapy both in vitro and in vivo. Cedric has a strong ability to plan, develop, and execute pre-clinical studies for oncology drugs with excellent communication skills, presentation abilities, and work ethic. A success-driven team player, he is able to work under pressure in order to meet deadlines and has established collaborations with both academic and pharmaceutical companies.
With an ambitious personality, Cedric’s goal is to develop selective therapeutic strategies for targeting AML/cancer stem cells in order to start clinical trials and improve patients’ outcomes. As proof, one of his preclinical studies led to a phase I/II clinical trial combining dasatinib with conventional chemotherapy aimed at improving outcomes in poor-risk AML patients that otherwise have low remission rates and high relapse rates (NCT01876953).
Seminars
- Leveraging existing MRD evidence from hematology (e.g. multiple myeloma) to inform regulatory and policy pathways in new settings
- Driving alignment on assays, thresholds, endpoints, and timepoints to ensure cross-study comparability and reproducibility
- Building collaborative frameworks and secure data-sharing models to generate the robust evidence required by regulators and payers
- Examining how ctDNA and MRD assays can serve as regulatory-acceptable biomarkers and support commercialization of CAR-T and T-cell engager therapies
- Addressing harmonization challenges across assay platforms and how standardization can streamline late-phase trials and companion diagnostic development
- Exploring opportunities for integrated, multi-omic bloodbased assays to provide scalable solutions that meet payer, regulatory, and clinician expectations
